| P50 | author | Kenneth Kendler | Q6390313 |
| | Anna R. Docherty | Q42593806 |
| | Francis A O'Neill | Q46434184 |
| | Dermot Walsh | Q113000839 |
| P2093 | author name string | Brien P Riley | |
| | Brion S Maher | |
| | Ayman H Fanous | |
| | Alexis C Edwards | |
| | Arden Moscati | |
| | Brandon K Wormley | |
| | Dawn L Thiselton | |
| | Donghyung Lee | |
| | Molecular Genetics of Schizophrenia Collaboration (MGS) | |
| | Silviu Bacanu | |
| | Teresa R de Candia | |
| | Tim B Bigdeli | |
| P2860 | cites work | A flexible and accurate genotype imputation method for the next generation of genome-wide association studies | Q21129496 |
| | An integrated map of genetic variation from 1,092 human genomes | Q22122153 |
| | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| | Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia | Q24336984 |
| | Tudor-SN interacts with and co-localizes with G3BP in stress granules under stress conditions | Q24339199 |
| | Biological insights from 108 schizophrenia-associated genetic loci | Q24561833 |
| | The NCBI dbGaP database of genotypes and phenotypes | Q24569609 |
| | ConsensusPathDB: toward a more complete picture of cell biology | Q24611619 |
| | Neuregulin 1 and susceptibility to schizophrenia | Q24616921 |
| | Genotype imputation with thousands of genomes | Q24633967 |
| | PLINK: a tool set for whole-genome association and population-based linkage analyses | Q24677407 |
| | The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response | Q24680794 |
| | Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies | Q28190066 |
| | Common polygenic variation contributes to risk of schizophrenia and bipolar disorder | Q28250609 |
| | Association of the NRG1 gene and schizophrenia: a meta-analysis | Q28300667 |
| | GATES: a rapid and powerful gene-based association test using extended Simes procedure | Q28741872 |
| | A genome-wide association study of neuroticism in a population-based sample | Q28750404 |
| | Genome-wide association study of the rate of cognitive decline in Alzheimer's disease | Q29416991 |
| | A comprehensive family-based replication study of schizophrenia genes | Q29417040 |
| | Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms | Q29417080 |
| | METAL: fast and efficient meta-analysis of genomewide association scans | Q29547217 |
| | Genetic and radiation hybrid mapping of the hyperekplexia region on chromosome 5q | Q30541673 |
| | Scapinin, the protein phosphatase 1 binding protein, enhances cell spreading and motility by interacting with the actin cytoskeleton | Q33401585 |
| | Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia | Q33662873 |
| | Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample | Q33692336 |
| | No association of dysbindin with symptom factors of schizophrenia in an Irish case-control sample | Q33809001 |
| | Association study of SNAP25 and schizophrenia in Irish family and case-control samples | Q33809007 |
| | The future of association studies: gene-based analysis and replication | Q33910011 |
| | Comprehensive gene-based association study of a chromosome 20 linked region implicates novel risk loci for depressive symptoms in psychotic illness | Q34119018 |
| | A separate disease within the syndrome of schizophrenia | Q34140437 |
| | A linear complexity phasing method for thousands of genomes | Q34237936 |
| | How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. | Q34253313 |
| | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents | Q34274859 |
| | Neuregulin and ErbB receptor signaling pathways in the nervous system | Q34278032 |
| | Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. | Q34304403 |
| | Dopamine in schizophrenia: a review and reconceptualization | Q34568816 |
| | Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study | Q34923924 |
| | Scapinin-induced inhibition of axon elongation is attenuated by phosphorylation and translocation to the cytoplasm | Q35011028 |
| | Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework | Q35993521 |
| | Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. | Q36189837 |
| | HYST: a hybrid set-based test for genome-wide association studies, with application to protein-protein interaction-based association analysis | Q36439328 |
| | Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia | Q36486414 |
| | No association between catechol-o-methyltransferase Val108/158Met polymorphism and schizophrenia or its clinical symptomatology in a Mexican population. | Q36511450 |
| | Neuregulin 1 genotype and schizophrenia | Q37076200 |
| | Concordance between chart review and structured interview assessments of schizophrenic symptoms | Q37118921 |
| | What we know: findings that every theory of schizophrenia should explain. | Q37159625 |
| | Molecular validation of the schizophrenia spectrum. | Q37451517 |
| | Autoimmune diseases and infections as risk factors for schizophrenia | Q38028598 |
| | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings | Q38124448 |
| | Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. | Q38133045 |
| | Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families | Q40126365 |
| | Toward New Approaches to Psychotic Disorders: The NIMH Research Domain Criteria Project | Q42399695 |
| | DIST: direct imputation of summary statistics for unmeasured SNPs | Q42931079 |
| | COMT genotype and manic symptoms in schizophrenia | Q43962494 |
| | Genome scan of three quantitative traits in schizophrenia pedigrees | Q44193613 |
| | No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). | Q44903036 |
| | Familiality of novel factorial dimensions of schizophrenia | Q45821746 |
| | Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains | Q47624828 |
| | Expression pattern of sorting Nexin 25 in temporal lobe epilepsy: a study on patients and pilocarpine-induced rats. | Q48115901 |
| | BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. | Q48127770 |
| | Mitochondrial DNA deletion mutations in patients with neuropsychiatric symptoms | Q48942369 |
| | Clinical symptomatology and the psychosis risk gene ZNF804A. | Q51849821 |
| | A genome-wide scan for modifier loci in schizophrenia. | Q51907532 |
| | Dysbindin genotype and negative symptoms in schizophrenia. | Q51920695 |
| | Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. | Q53654455 |
| | Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia | Q81299308 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 279-287 | |
| P577 | publication date | 2015-08-27 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes | |
| P478 | volume | 42 | |